Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q6NN
|
|||
| Former ID |
DIB018040
|
|||
| Drug Name |
TAK-070
|
|||
| Synonyms |
UNII-PNM9E64544; PNM9E64544; TAK-070; (2R)-N,N-Dimethyl-6-(4-biphenylylmethoxy)-1,2,3,4-tetrahydronaphthalene-2alpha-ethanamine; TAK-070 free base; N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine; N,N-Dimethyl-2-((2R)-6-((4-phenylphenyl)methoxy)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine; SCHEMBL361018; GTPL6940; 212571-56-7; J3.229.705F; 2-((2R)-6-(4-Biphenylylmethoxy)-1,2,3,4-tetrahydro-2-naphthalenyl)-N,N-dimethylethanamine; 2-Naphthaleneethanamine, 6-((1,1'-biphenyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Clinical trial | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C27H34ClNO2
|
|||
| Canonical SMILES |
CN(C)CCC1CCC2=C(C1)C=CC(=C2)OCC3=CC=C(C=C3)C4=CC=CC=C4.O.Cl
|
|||
| InChI |
1S/C27H31NO.ClH.H2O/c1-28(2)17-16-21-8-13-26-19-27(15-14-25(26)18-21)29-20-22-9-11-24(12-10-22)23-6-4-3-5-7-23;;/h3-7,9-12,14-15,19,21H,8,13,16-18,20H2,1-2H3;1H;1H2/t21-;;/m0../s1
|
|||
| InChIKey |
VBMPTAUGUUBFJK-FGJQBABTSA-N
|
|||
| CAS Number |
CAS 365276-12-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Beta-secretase (BACE) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.